Press releases

8 Nov 2024

Transparency notification BlackRock, Inc.

5 Nov 2024

UCB completes sale of established brands and updates 2024 financial guidance

31 Oct 2024

UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024

22 Oct 2024

UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

14 Oct 2024

UCB receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX[®] (bimekizumab-bkzx)

11 Oct 2024

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and MGFA Scientific Session

Press releases

Press releases

Search Press releases

Transparency notification BlackRock, Inc.

UCB completes sale of established brands and updates 2024 financial guidance

UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024

UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

UCB receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX[®] (bimekizumab-bkzx)

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and MGFA Scientific Session

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Transparency notification BlackRock, Inc.

UCB completes sale of established brands and updates 2024 financial guidance

UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024

UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

UCB receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX[®] (bimekizumab-bkzx)

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and MGFA Scientific Session

Choose a Country